Research & Development

CIT-013 Clinical Development

Citryll has identified multiple antibodies targeting NETosis. Our lead target, CIT-013, is currently under clinical development and expected to start Phase 2a Proof-of-Concept studies in Rheumatoid Arthritis and Hidradenitis Suppurativa later this year.

Phase 1 - First in Human Studies

Q3 2022 - finalized

Single Ascending Dose
in healthy volunteers

CIT-013 was well tolerated within therapeutic window, PK as expected.
Q3 2022 - finalized

Q4 2022 - finalized

LPS Challenge
in healthy volunteers

Study showed excellent target engagement via complete suppression of LPS-induced NETs and target engagement.

Q4 2022 - finalized

Q1 2023 - finalized

Subcutaneous Single Dosing
in healthy volunteers

CIT-013 well-tolerated, good bioavailability.

Q1 2023 - finalized

Q3 2024 - expected end

Repeat Dosing
In Rheumatoid Arthritis patient volunteers

Ongoing study.

Q3 2024 - expected end

Phase 2a

November 2024 - expected start

Proof of Concept
in Rheumatoid Arthritis

November 2024 - expected start

February 2025 - expected start

Proof of Concept
in Hidradenitis Suppurativa

February 2025 - expected start

Future development opportunities

After successful demonstration of clinical proof-of-concept of our NETosis and NET targeting approach in RA and HS, there are opportunities to expand development into other inflammatory diseases in which NETs play a pathogenic role.